SG11201801111RA - Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition - Google Patents

Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition

Info

Publication number
SG11201801111RA
SG11201801111RA SG11201801111RA SG11201801111RA SG11201801111RA SG 11201801111R A SG11201801111R A SG 11201801111RA SG 11201801111R A SG11201801111R A SG 11201801111RA SG 11201801111R A SG11201801111R A SG 11201801111RA SG 11201801111R A SG11201801111R A SG 11201801111RA
Authority
SG
Singapore
Prior art keywords
pharmaceutical composition
composition used
reducing localised
fat
localised fat
Prior art date
Application number
SG11201801111RA
Other languages
English (en)
Inventor
Yu-Fang Ling
Original Assignee
Caliway Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58186932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201801111R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/CN2015/088340 external-priority patent/WO2016029870A1/zh
Application filed by Caliway Biopharmaceuticals Co Ltd filed Critical Caliway Biopharmaceuticals Co Ltd
Publication of SG11201801111RA publication Critical patent/SG11201801111RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/11—Encapsulated compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201801111RA 2015-08-28 2016-08-26 Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition SG11201801111RA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/CN2015/088340 WO2016029870A1 (zh) 2014-08-28 2015-08-28 用于减少局部脂肪与减少体重的组合物及其医药品与应用
US201562257846P 2015-11-20 2015-11-20
US201662299702P 2016-02-25 2016-02-25
PCT/IB2016/055102 WO2017037594A2 (zh) 2015-08-28 2016-08-26 用于减少局部脂肪的医药组成物及其用途

Publications (1)

Publication Number Publication Date
SG11201801111RA true SG11201801111RA (en) 2018-03-28

Family

ID=58186932

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201801111RA SG11201801111RA (en) 2015-08-28 2016-08-26 Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition

Country Status (15)

Country Link
US (4) US20180243211A1 (ko)
EP (2) EP3381451A4 (ko)
JP (5) JP7063803B2 (ko)
KR (4) KR102356390B1 (ko)
CN (3) CN109069655A (ko)
AU (5) AU2016314545C1 (ko)
BR (2) BR112018003892A2 (ko)
CA (2) CA2995158C (ko)
CO (1) CO2018003424A2 (ko)
IL (1) IL257784B2 (ko)
MX (3) MX2018002461A (ko)
RU (1) RU2753507C2 (ko)
SG (1) SG11201801111RA (ko)
TW (3) TWI604859B (ko)
WO (2) WO2017037593A2 (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10537548B2 (en) 2014-08-28 2020-01-21 Caliway Biopharmaceuticals Co., Ltd. Composition and medical product for reducing body weight and body fat, and use of said product
US11318110B2 (en) 2015-08-28 2022-05-03 Caliway Biopharmaceuticals Co., Ltd. Pharmaceutical composition for reducing local fat and uses thereof
WO2017037593A2 (zh) 2015-08-28 2017-03-09 康霈生技股份有限公司 用于减少局部脂肪的医药组成物及其用途
CA3033041A1 (en) 2016-08-26 2018-03-01 Caliway Biopharmaceuticals Co., Ltd. A subcutaneous injection formulation for reducing body weight and uses thereof
WO2018094253A1 (en) 2016-11-18 2018-05-24 Pacira Pharmaceuticals, Inc. Zinc meloxicam complex microparticle multivesicular liposome formulations and processes for making the same
CN110446492A (zh) * 2017-03-28 2019-11-12 康霈生技股份有限公司 用于减少体重及减少体脂肪的组合物及其医药品与应用
ES2976407T3 (es) * 2019-02-11 2024-07-31 Joseph Halstead Soluciones de curcuminoides no acuosas en dosis altas administrables terapéuticamente
US20220184170A1 (en) 2019-03-24 2022-06-16 NaishadhKumar Ramubhai Patel Formulation to enhance the bioavailibity and stability of curcuminoids and/or its derivatives thereof
CN110934827B (zh) * 2019-11-08 2021-03-19 江西中医药大学 一种口服葛根素混合胶束制剂、制备方法及应用
CN113730650B (zh) * 2021-10-13 2022-11-01 哈尔滨泽润医疗机构管理有限公司 一种碳水溶酶组合物及其制备方法和应用
WO2023192259A1 (en) * 2022-03-28 2023-10-05 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synergy for increasing insulin sensitivity
TW202408465A (zh) * 2022-05-16 2024-03-01 康霈生技股份有限公司 用於緩解由脂肪組織或脂肪的異常皮下沉積所引起的病狀之組合物及方法
US20240165050A1 (en) * 2022-11-22 2024-05-23 Caliway Biopharmaceuticals Co., Ltd. Method for treating and/or preventing edematous fibrosclerotic panniculopathy

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048736A (en) * 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
CN100335122C (zh) * 1999-03-03 2007-09-05 伊莱利利公司 含有成胶束表面活性剂的棘白菌素药物制剂
ATE346059T1 (de) * 1999-08-16 2006-12-15 Dsm Ip Assets Bv Verfahren zu herstellung von epigallocatechin gallate
US6475530B1 (en) * 2000-05-31 2002-11-05 Eric H. Kuhrts Methods and compositions for producing weight loss
US6383482B1 (en) * 2000-08-24 2002-05-07 Vitacost.Com, Inc. Weight loss composition containing green tea, hydroxycitric acid, 5-hydroxytryptophan, glucomannan, picolinate and lactobacillus
US20040071799A1 (en) 2001-02-12 2004-04-15 Xiurong Xu Herbal compositions and methods for effecting weight loss in humans
JP4179494B2 (ja) 2001-10-23 2008-11-12 株式会社カネカ ペルオキシソーム増殖剤応答性受容体リガンド剤
US20040146539A1 (en) 2003-01-24 2004-07-29 Gupta Shyam K. Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits
US20060121158A1 (en) 2003-06-04 2006-06-08 Mario Ferruzzi Weight management beverage
CN100539988C (zh) * 2003-06-27 2009-09-16 株式会社太平洋 含有生理活性成分的自聚集聚合物纳米颗粒和含有该纳米颗粒的外用搽剂
CN101247793B (zh) 2003-12-29 2013-04-10 哈佛大学校长及研究员协会 治疗或预防肥胖和胰岛素抗性病症的组合物
US20050232974A1 (en) * 2004-04-19 2005-10-20 Gore Makarand P System and a method for pharmaceutical dosage preparation using jettable microemulsions
WO2005113069A2 (en) * 2004-05-14 2005-12-01 Research Development Foundation Use of circumin and analogues as inhibitors of acc2
CN100486567C (zh) * 2004-08-12 2009-05-13 山东绿叶天然药物研究开发有限公司 姜黄素乳剂及其制备方法
US20060188590A1 (en) 2005-01-05 2006-08-24 Mitsunori Ono Compositions for treating diabetes or obesity
CA2596171C (en) * 2005-02-04 2013-10-08 Peter Heger Use of an active ingredient combination that contains hydroxystilbene for preventing and/or treating diseases
ITFI20050031A1 (it) 2005-02-21 2006-08-22 Stefan Coccoloni Una composizione farmaceutica atta a prevenire l'invecchiamento e l'insorgere di malattie vascolari,neoplastiche,cutanee e dell'apparato pilifero
US7829554B2 (en) 2005-07-14 2010-11-09 Lithera, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
JP2007063137A (ja) * 2005-08-29 2007-03-15 Daicho Kikaku:Kk 抗肥満薬
WO2007041276A2 (en) 2005-09-29 2007-04-12 New Chapter, Inc. Methods for modulating apoptosis, cellgrowth, and protein expression with herbal compositions
JP2007131603A (ja) 2005-11-14 2007-05-31 Kaneka Corp Ｌ−カルニチン合成系酵素遺伝子の転写促進用組成物
CN100367951C (zh) * 2005-12-16 2008-02-13 石药集团恩必普药业有限公司 丁苯酞静脉乳剂及其应用
US9192644B2 (en) * 2006-03-06 2015-11-24 The Regents Of The University Of California Bioavailable curcuminoid formulations for treating Alzheimer's disease and other age-related disorders
CA2656997A1 (en) 2006-03-31 2008-10-11 Dsm Ip Assets B.V. Novel use of compounds and combinations of compounds for improving the physical appearance
US7977319B1 (en) 2006-04-03 2011-07-12 Scott David Levine Ultra-high fiber supplement and method of reducing weight, cardiovascular risks and ingested toxins
WO2007113008A2 (en) * 2006-04-04 2007-10-11 Dsm Ip Assets B.V. Opaque container comprising food or pharmaceutical products or herbal(s)
CN101095665A (zh) 2006-06-27 2008-01-02 中国科学院上海生命科学研究院 Sirt1在预防、控制或治疗肥胖中的用途
US7923026B2 (en) * 2006-10-20 2011-04-12 Solvay Pharmaceuticals B.V. Embedded micellar nanoparticles
KR101069502B1 (ko) * 2006-10-31 2011-09-30 (주)아모레퍼시픽 비만 및 당뇨병 개선용 경구용 조성물
JP2008133272A (ja) * 2006-10-31 2008-06-12 Ito En Ltd Ｃｐｔ活性亢進剤及び飲食物
CN101310718A (zh) * 2007-05-23 2008-11-26 中国科学院上海生命科学研究院 减肥降血脂的含儿茶素的组合物及其用途
CN102357226B (zh) 2007-08-07 2013-07-10 北京北大维信生物科技有限公司 中草药姜黄的醇提取物在制备具有脂肪酶活性抑制作用的药物中的应用
WO2009066303A2 (en) * 2007-11-22 2009-05-28 Ganga Raju Gokaraju New synergistic phytochemical composition for the treatment of obesity
EP2249806A2 (en) * 2008-01-08 2010-11-17 Sirtris Pharmaceuticals, Inc. Resveratrol formulations
WO2009146218A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
AU2009262729B2 (en) * 2008-06-25 2013-11-14 Elc Management Llc Method and compositions for improving skin and body appearance
AU2009307753A1 (en) 2008-10-22 2010-04-29 Metaproteomics, Llc Novel mitochondrial uncoupling methods and compositions for enhancing adipocyte thermogenesis
US8496974B2 (en) * 2008-11-25 2013-07-30 Oy Granula Ab Ltd Method for preparing a composition comprising a compound mixture and a carrier agent
WO2010062824A2 (en) * 2008-11-26 2010-06-03 Lipoprotein Technologies, Inc. Enhanced bioactive formulations of resveratrol
WO2010106191A1 (en) * 2009-03-20 2010-09-23 Bioxtract S.A. Pharmaceutical composition presenting anti-inflammatory properties
CN101874763A (zh) * 2009-04-29 2010-11-03 上海家化联合股份有限公司 一种白藜芦醇柔性脂质体及其制备方法
KR20100124519A (ko) * 2009-05-19 2010-11-29 (주)아모레퍼시픽 녹차 추출물을 함유하는 조성물
CN101632655B (zh) 2009-08-04 2011-12-07 南京大渊美容保健有限公司 延缓衰老的白藜芦醇和生物类黄酮营养组合物
JP5594819B2 (ja) 2009-12-22 2014-09-24 キリンホールディングス株式会社 脂質代謝改善用組成物
AU2011224558B2 (en) * 2010-03-10 2014-02-27 Abbvie Ireland Unlimited Company Solid compositions
US8835509B2 (en) * 2010-05-31 2014-09-16 Arbro Pharmaceuticals Ltd. Self emulsifying drug delivery system for a curcuminoid based composition
EP2588101B1 (en) 2010-07-02 2014-10-22 Helix Biomedix, Inc. N-acyl amino acid derivatives for treating skin conditions such as cellulite
CA2840891A1 (en) * 2010-07-02 2012-01-05 Eric Hauser Kuhrts Stable fatty acid-containing formulations
KR101640258B1 (ko) * 2010-07-05 2016-07-15 주식회사 엘지생활건강 적포도 추출물, 녹차 추출물, 대두 추출물 및 ｌ－카르니틴을 유효성분으로 함유하는 항비만 조성물
EP2593093A1 (en) 2010-07-16 2013-05-22 Merz Pharma GmbH & Co. KGaA Use of a cationic amphiphilic drug for the preparation of a formulation for the reduction of subcutaneous adipose tissue
WO2012050978A1 (en) * 2010-09-29 2012-04-19 MyCell Holdings Limited Formulations of ubiquinol and resveratrol esters
CN102106816A (zh) * 2010-12-16 2011-06-29 天津迈迪瑞康生物医药科技有限公司 一种白藜芦醇纳米制剂及其制备方法
US8815310B2 (en) 2011-01-10 2014-08-26 Morteza Naghavi Compositions for boosting metabolism, assisting weight loss, and promoting cardiovascular health
CN102512404B (zh) 2011-11-18 2014-05-07 上海交通大学 一种姜黄素类化合物肺靶向制剂及其制备方法与应用
WO2013100111A1 (ja) 2011-12-27 2013-07-04 油田 正樹 サーチュイン活性化剤
ES2739194T3 (es) * 2012-01-19 2020-01-29 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulación y método para aumentar la biodisponibilidad oral de fármacos
US8496979B1 (en) 2012-02-02 2013-07-30 Reliv International, Inc. Caffeine-free dietary supplements for increasing energy and methods of administering the same
CN104125848A (zh) 2012-02-29 2014-10-29 雅芳产品公司 Cpt-1调节剂的用途及其组合物
US8652518B2 (en) 2012-04-15 2014-02-18 Jahahreeh Finley Compositions and methods for the prevention and treatment of diseases or conditions associated with oxidative stress, inflammation, and metabolic dysregulation
WO2014025672A1 (en) 2012-08-04 2014-02-13 Eric Hauser Kuhrts Water-soluble lipophilic natural compound formulations
WO2014028607A1 (en) * 2012-08-14 2014-02-20 Abbott Laboratories Low glycemic index nutritional compositions for preserving muscle mass and improving body composition in diabetics
US9211298B2 (en) 2012-11-16 2015-12-15 Song Gao Compositions containing enriched natural crocin and/or crocetin, and their therapeutic or nutraceutical uses
DE202012012130U1 (de) * 2012-12-19 2014-03-21 Aquanova Ag Curcuminsolubilisat
WO2014138426A2 (en) * 2013-03-07 2014-09-12 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
CN103285401A (zh) * 2013-05-27 2013-09-11 沈阳药科大学 一种能提高难溶性药物溶解性和生物利用度的组合物
US9458086B1 (en) * 2013-07-03 2016-10-04 University Of South Florida (A Florida Non-Profit Corporation) Compositions and methods for adipocyte modulation
US10226413B2 (en) 2013-11-15 2019-03-12 Damy Chemical Co., Ltd. Solution solubilization composition of insoluble material and method for solubilizing insoluble material using same
CA2931255A1 (en) * 2013-11-27 2015-06-04 Research Foundation Of The City University Of New York Activity enhancing curcumin compositions and methods of use
TW201540294A (zh) * 2014-04-25 2015-11-01 Caliway Biomedical Co Ltd 用於抑制脂肪細胞、降低體脂肪、減少體重或促進脂肪代謝之植物萃取組成物及其醫藥組合物與用途
CN103989659B (zh) * 2014-05-26 2016-09-07 重庆医科大学 姜黄素纳米结构脂质载体及其制备方法
PL3187178T3 (pl) * 2014-08-28 2022-11-21 Caliway Biopharmaceuticals Co. Ltd. Kompozycja oraz leki do zmniejszania ilości zlokalizowanej tkanki tłuszczowej i masy ciała oraz ich zastosowanie
US10226503B2 (en) 2014-08-28 2019-03-12 Caliway Biopharmaceuticals Co., Ltd. Plant extract composition for reducing topical fat and promoting weight loss as well as applications thereof
JP6446552B2 (ja) * 2014-08-28 2018-12-26 カリウェイ バイオファーマシューティカルズ カンパニー リミテッド 体重と体脂肪減少に用いられる組成物およびその医薬品と使用
WO2017037593A2 (zh) 2015-08-28 2017-03-09 康霈生技股份有限公司 用于减少局部脂肪的医药组成物及其用途
US11318110B2 (en) 2015-08-28 2022-05-03 Caliway Biopharmaceuticals Co., Ltd. Pharmaceutical composition for reducing local fat and uses thereof
CA3033041A1 (en) 2016-08-26 2018-03-01 Caliway Biopharmaceuticals Co., Ltd. A subcutaneous injection formulation for reducing body weight and uses thereof

Also Published As

Publication number Publication date
KR102107917B1 (ko) 2020-05-08
WO2017037593A2 (zh) 2017-03-09
AU2016314546B2 (en) 2019-09-12
JP2018533545A (ja) 2018-11-15
AU2016314545B2 (en) 2019-07-11
US20220362173A1 (en) 2022-11-17
KR20200032768A (ko) 2020-03-26
MX2021010359A (es) 2021-10-01
CA2995155C (en) 2021-05-11
JP7095903B2 (ja) 2022-07-05
IL257784B2 (en) 2023-11-01
BR112018003892A2 (pt) 2018-09-25
RU2019108198A3 (ko) 2020-09-21
TW201806584A (zh) 2018-03-01
KR102240221B1 (ko) 2021-04-14
AU2021202349B2 (en) 2022-12-08
AU2019246808B2 (en) 2021-01-28
US20180250243A1 (en) 2018-09-06
EP3381473A4 (en) 2019-10-09
US20200163906A1 (en) 2020-05-28
JP2020128404A (ja) 2020-08-27
TWI604859B (zh) 2017-11-11
KR102356390B1 (ko) 2022-02-08
JP7063803B2 (ja) 2022-05-09
CA2995158C (en) 2021-05-11
WO2017037594A3 (zh) 2018-08-23
AU2019280037B2 (en) 2021-02-18
CA2995155A1 (en) 2017-03-09
US20180243211A1 (en) 2018-08-30
CN108697668A (zh) 2018-10-23
KR20180039167A (ko) 2018-04-17
BR112018003877A2 (pt) 2018-09-25
JP2018531220A (ja) 2018-10-25
AU2016314545C1 (en) 2021-09-23
AU2021202349A1 (en) 2021-05-13
MX2018002461A (es) 2018-06-07
AU2016314546A1 (en) 2018-03-01
TW201707685A (zh) 2017-03-01
JP2019528297A (ja) 2019-10-10
EP3381451A4 (en) 2019-10-09
TW201707686A (zh) 2017-03-01
KR20200049882A (ko) 2020-05-08
CN108697668B (zh) 2022-11-04
US11433034B2 (en) 2022-09-06
AU2016314546C1 (en) 2021-07-22
AU2019246808A1 (en) 2019-10-31
JP7063804B2 (ja) 2022-05-09
US10610496B2 (en) 2020-04-07
RU2753507C2 (ru) 2021-08-17
JP7054540B2 (ja) 2022-04-14
EP3381451A2 (en) 2018-10-03
AU2019280037A1 (en) 2020-01-16
IL257784A (en) 2018-06-28
CO2018003424A2 (es) 2018-07-10
RU2019108198A (ru) 2020-09-21
EP3381473A2 (en) 2018-10-03
TWI667044B (zh) 2019-08-01
CN115778928A (zh) 2023-03-14
JP2020143091A (ja) 2020-09-10
KR20180037058A (ko) 2018-04-10
CA2995158A1 (en) 2017-03-09
CN109069655A (zh) 2018-12-21
WO2017037594A2 (zh) 2017-03-09
MX2018002462A (es) 2018-06-19
AU2016314545A1 (en) 2017-11-16
IL257784B1 (en) 2023-07-01
WO2017037593A3 (zh) 2018-08-23
TWI630922B (zh) 2018-08-01

Similar Documents

Publication Publication Date Title
IL257784A (en) Methods and compositions for reducing fat
ZA201707981B (en) Compositions of obeticholic acid and methods of use
SG11201706766WA (en) Materials and methods for treatment of hemoglobinopathies
HK1252567A1 (zh) 被取代的苯甲酰胺和其使用方法
RS65120B1 (sr) Farmaceutske formulacije i postupci za njihovu upotrebu
HK1250950A1 (zh) 曲美他嗪在製備防治肝病的藥物中的用途
IL280690A (en) Pharmaceutical preparations that include DGLA and their use
HK1252405A1 (zh) 用於減少脂肪量的β-羥基-β-甲基丁酸(HMB)的組合物和使用方法
HK1258502A1 (zh) 用於治療高胱氨酸尿症的組合物和方法
IL259710A (en) Preparations and methods for the treatment of Davidson's disease (microvillus inclusion disease) and related diseases
HK1217303A1 (zh) 種治療白血病的藥物組合物及其製備方法
HK1258056A1 (zh) 治療性化合物和其使用方法
HK1245094A1 (zh) 一種治療抑鬱症的藥物組合物及其製備方法
GB201511799D0 (en) Composition and methods of treatment
PT3503885T (pt) Composição farmacêutica e métodos de utilização
SG11201610383YA (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
GB201718483D0 (en) Pharmaceutical composition for treatment of meopausal syndrome and preparation method thereof
HK1256840A1 (zh) 含有蛋白的外用皮膚組合物和使用方法
HK1244224B (zh) Mek抑制劑的藥物組合物及其製備方法
IL257689A (en) Pharmacological preparations and methods for the treatment of diseases associated with hypoxia
IL247645A0 (en) Preparations of seleno-organic compounds and methods of using them
SG11201706369PA (en) Compositions and methods for the treatment of mucositis
GB201408738D0 (en) Components and methods for formulation of components